Novel classes of bronchodilators
| Class | Molecule | Potential Therapeutic Effects |
|---|---|---|
| TAS2R agonists | Erythromycin | Bronchodilation, reduction in exercise- or histamine-induced bronchoconstriction in patients with asthma |
| Arisoprodol | ||
| Flufenamic acid | ||
| Dapsone | ||
| Quinine | ||
| Chloroquine | ||
| Caffeine | ||
| Azelastine | ||
| Colchicine | ||
| EP receptor 4 agonists | ONO-AE1-329 | Relaxation of ASM, reversal of histamine-induced contraction of ASM, increase in glucocorticoid response element-dependent transcription when combined with ICS |
| L-902688 | ||
| TCS2510 | ||
| Rivenprost | ||
| Rho kinase inhibitors | Fasudil | Relaxation of ASM, relaxation of methacholine-constricted human small airways |
| Ripasudil | ||
| Netarsudil | ||
| AMA0076/PHP-201 | ||
| Y-39983 | ||
| Calcilytics | Calcityrol, B2.1-E1 | Bronchodilator and anti-inflammatory actions |
| Agonists of PPARγ | Pioglitazone | Relaxation of ASM, inhibition of the initiation and development of a maximal contraction induced by methacholine, synergistic interaction with β2-AR agonists on ASM cell proliferation |
| Rosiglitazone | ||
| Troglitazone | ||
| Ciglitazone | ||
| RXFP1 agonists | Serelaxin | Relaxation of ASM, increase in airway dilator responsiveness to β-AR agonists |
| B-chain only agonists (B7-33) | ||
| Small molecule RXFP1 agonists (ML290) | ||
| Fatty acid conjugated relaxin-2 analogs (R9-13) | ||
| sGC activators | BAY 41-2272 | Bronchodilation, reduction of airway hyperresponsiveness |
| BAY 60-2770 | ||
| BAY 58-2667 | ||
| Pepducins | Pepducin ICL3-9 | Relaxation of ASM |
| AT1-2341 | ||
| P4pal-10 |